Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.41 |
| ▸ | KDM4A | O75164 | 1/20 | 0.41 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.41 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23806957 | 1.00 | KDM4C (0.41) | KDM4CKDM4APHF8KDM2ALMNA | |
| SCHEMBL29300277 | 0.91 | EPHX2 (0.36) | KDM4CKDM4APHF8KDM2ALMNA | |
| SCHEMBL22509628 | 0.88 | KDM4C (0.33) | KDM4CKDM4APHF8KDM2ALMNA | |
| SCHEMBL23613254 | 0.86 | KDM4C (0.39) | KDM4CKDM4APHF8KDM2ALMNA | |
| SCHEMBL25971286 | 0.86 | KDM4C (0.35) | KDM4CKDM4APHF8KDM2ALMNA | |
| SCHEMBL21868829 | 0.85 | KDM4C (0.31) | KDM4CKDM4APHF8KDM2A | |
| SCHEMBL29300289 | 0.84 | KDM4C (0.37) | KDM4CKDM4APHF8KDM2A | |
| SCHEMBL22986134 | 0.81 | DNM1 (0.34) | LMNA | |
| SCHEMBL25831236 | 0.81 | KDM4C (0.34) | KDM4CKDM4APHF8KDM2ALMNA | |
| SCHEMBL25445913 | 0.80 | ALDH1A1 (0.33) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234953-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-07-27 | — | — | US | disclosed |
| US-20230135894-A1 | MK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230135894-A1 | MK2 DEGRADERS AND USES THEREOF | MKNK2, MKRN3, DUS2 | KDM4C 847/4885KDM4A 505/4885PHF8 1408/4885 |
| US-20230234953-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | KDM4C 293/4885KDM4A 104/4885PHF8 957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.